[CLSTR]
< Back to situations

[ORGANIZATION]

AbbVie

Featured in 17 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US]

AbbVie immunology pipeline and strategic transition

2 clusters · 4 sources · last updated

Latest: AbbVie completes $10.9 billion acquisition of Apogee Therapeutics

AbbVie is undergoing a strategic transition to mitigate the impact of biosimilar competition on its blockbuster drug, Humira. Following a decline in Humira sales to $6.4 billion in 2025, the company has relied on the gro

[QUIET] [HEALTH] [CN] [US]

Upadacitinib clinical trials for alopecia areata

2 clusters · 7 sources · last updated

Latest: Upadacitinib shows effectiveness in treating severe alopecia areata

Clinical trials for the drug upadacitinib, a Janus kinase (JAK) inhibitor originally developed for rheumatoid arthritis, have demonstrated significant success in treating severe alopecia areata. Phase 3 clinical program

[QUIET] [CULTURE] [CZ]

Czech Republic health and social service events

2 clusters · 6 sources · last updated

Latest: Czech Republic health and social service events scheduled for September 2026

In September 2026, the Czech Republic is hosting several health and social service initiatives across various regions. In South Bohemia, the South Bohemian Health and Prevention Day is scheduled for September 17 in Česk

[QUIET] [BUSINESS]

High trading volumes in manufacturing, healthcare, and EV

6 clusters · 6 sources · last updated

Latest: Medical stocks Boston Scientific and McKesson see high trading volume

Market activity continues to show high trading volumes across several key sectors, including manufacturing, pharmaceuticals, electric vehicles, and healthcare. In the manufacturing and semiconductor sectors, significant

[QUIET] [BUSINESS] [US]

Institutional investment activity in technology stocks

2 clusters · 6 sources · last updated

Latest: Corporate earnings and institutional shifts impact Adobe, Axon, and Ulta Beauty

Institutional investors continue to adjust holdings across major technology firms, with recent activity involving shifts in Apple, Adobe, and Intuit positions. While firms like GKV Capital Management Co. Inc. and Allen C

[QUIET] [HEALTH]

Upadacitinib clinical trials for alopecia areata

3 clusters · 12 sources · last updated

Latest: Upadacitinib shows significant hair regrowth in severe alopecia areata trials

Two phase 3 clinical trials, UP-AA1 and UP-AA2, have demonstrated that the JAK inhibitor upadacitinib (brand name Rinvoq) shows significant promise in treating severe alopecia areata. The studies, published in JAMA Derma

[QUIET] [HEALTH] [AE] [US]

Rinvoq approval for vitiligo treatment

2 clusters · 3 sources · last updated

Latest: UAE approves first oral medication for vitiligo treatment

The United Arab Emirates has granted approval for the oral use of Rinvoq (upadacitinib) to treat non-segmental vitiligo. This marks the first time the medication has been approved for oral use for this condition globally

Also covered in